Description: This structure represents a major breakthrough in targeted oncology, revealing the binding mode of INCB159020, a novel orally bioavailable inhibitor targeting the oncogenic KRAS G12D mutation. The high-resolution structure (1.36 Å) provides critical insights for structure-based drug design in pancreatic and colorectal cancers.